Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Imugene Limited ( (AU:IMU) ) has issued an update.
Imugene Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX), with a total of 18,221,721 ordinary fully paid shares being listed. This move is expected to provide the company with additional capital to further its research and development efforts in cancer immunotherapy, potentially strengthening its market position and providing value to its stakeholders.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing on the development and commercialization of immunotherapies for the treatment of cancer. The company is known for its innovative approach to cancer treatment, leveraging the immune system to target and destroy cancer cells.
YTD Price Performance: 50.0%
Average Trading Volume: 160,971
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $207.6M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.
